88P Efficacy of olaparib in advanced cancers occurring in patients with germline or somatic tumor mutations in homologous recombination (HR) genes, a Belgian Precision phase II basket study

Abstract

PARP inhibition with olaparib is a treatment with high efficacy in HR deficient cancers that arise in carriers of a germline mutation in the BRCA1/2 genes, particularly in ovarian cancer, a registered indication. Olaparib is also active in other BRCA1/2 mutation related cancers, including breast, prostate and pancreatic cancer. Olaparib acts through synthetic lethality in HR deficient cancers. Olaparib responses have however also been documented in cancers in which no BRCA1/2 mutations were found.